• S. M. Kartashov
  • T. V. Bazarіnska
  • M. Ye. Tymchenko
  • S. M. Gramatyuk
Keywords: cancer cells, ovarian cancer, lymphatic system, surgical treatment.


Summary. The aim of the study was to study the effect of clinical and morphological factors on diagnosis and onset of disease recurrence.

Materials and methods. To achieve this goal, we formed a sample of postoperative samples of ovarian tumor tissue, which were divided into 3 groups: comparison group — ovarian cancer (T1-3N0M0, T1-3N0M1) (РЯ n = 261) main group 1 — borderline ovarian tumor (T1-3N0M0) (singing n = 100); the main group 2 — benign tumors of the ovaries (DOYA n = 40). The age of patients ranged from 23 to 62 years. Of these, 50 % were women of childbearing age — from 23 to 36 years (n = 26). The comparison group included 46 patients diagnosed with ovarian cancer aged 35 to 78 years. Among them, the age group from 30 to 40 years old was 14 % (n = 6). Most of the observations — 56 % (n = 24) — occurred in patients aged 40-60 years. Women over 60 made up 30 % (n = 14).

Results and discussion. Ovarian cancer in the structure of the female genital organs malignancy is characterized by an ambiguous forecast and the highest mortality rate. The leading factors determining this phenomenon are the features of tumor metastasis. Metastasis of ovarian cancer occurs at the early stages of the disease and runs a variety of ways: contact, intraperitoneal, haemacirculatory and through the lymphatic system. Such features are determined by the topography of metastatic disease, anatomy, blood supply and lymphatic channel of the female reproductive gland. The greater omentum plays the barrier role in the development of the pathological process of the abdomen. At present poor prognosis and poor treatment outcomes require reviewing approaches to the surgical treatment of ovarian cancer. In this connection defining the features of ovarian cancer metastasis provides an opportunity to find new ways to disable malignant cells distribution.

Conclusions. A key role in the treatment of ovarian cancer has surgery, chemotherapy, and targeted therapy. Adequate staging is important in choosing treatment tactics and assessing the prevalence of the disease. The importance of genetic and molecular studies is growing, according to the results of which it is possible to predict an increased risk of developing OC, to individualize and adjust treatment regimens.


1. The writing committee on behalf of the ASTEC study group // Lancet.— 2009.— Vol. 373.— P. 125–136.
2. Рак в Україні, 2015–2016. Захворюваність, смертність, показники діяльності онкологічної служби; уклад.: З. П. Федоренко, Л. О. Гулак, Ю. Й. Михайлович [та ін.] // Бюл. Нац. канцер-реєстру України.— К., 2016.— № 18.— 123 с.
3. FIGO committee on Gynaecologic Oncology // Int. J. Gynaecol. Obstet.— 2009.— Vol. 105.— P. 103–104.
4. Reuss A, du Bois A, Harter P, et al. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). Int J Gynecol Cancer 2019. DOI:
5. Kadhel P, Revaux A, Carbonnel M, et al. An update on preoperative assessment of the resectability of advanced ovarian cancer. Horm Mol Biol Clin Investig 2019. DOI:–0032.
6. Voigt S, Hüttig F et al. Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benignprostate hyperplasia? Prostate. 2011 Sep;71(12):1325-31. doi: 10.1002/pros.21349. Epub 2011 Feb 9.
7. Morita M, Matsuura T. Successful Treatment of Incidental Prostate Cancer by Radical Transurethral Resection of Prostate Cancer. Clin Genitourin Cancer. 2012 Nov 5. pii: S1558-7673(12)00212-1. doi: 10.1016/j.clgc.2012.09.012.
8. Dubynina V. Tactic of resistant ovarian cancer palliative treatment in elderly patients / V. Dubynina, O. Kuznetsova, A. Rybin // MASCC/ISOO (Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology) International Symposium on Supportive Care in Cancer. June 27-29, 2013. Berlin, Germany. - Support Care Cancer. - 2013. - V. 21, suppl. 1. - doi: 10.1007/s00520-013-1798-3.
9. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer. (2007) 96:1817–22. doi: 10.1038/sj.bjc.6603803.
10. Isonishi S, Niimi S, Sasaki H, Ochiai K, Yasuda M, Tanaka T. Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer. Gynecol Oncol. (2004) 93:647–52. doi: 10.1016/j.ygyno.2004.03.006.
11. Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Jpn J Clin Oncol. (2015) 45:49–60. doi: 10.1093/jjco/hyu175.
12. Eoh KJ, Lee JY, Yoon JW, Nam EJ, Kim S, Kim SW, et al. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: reappraisal in the era of radical surgery. Oncotarget. (2017) 8:37807–16. doi: 10.18632/oncotarget.13696.
13. Spiliotis JD, Iavazzo C, Kopanakis ND, et al. Secondary debulking for ovariancarcinoma relapse: The R-R dilemma — is the prognosis different for residual or recurrent disease. J Turk Ger Gynecol Assoc 2019. DOI: 10.4274/jtgga.galenos.2019.2018.0165.
14. du Bois A, Baert T, Vergote I. Role of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. J Clin Oncol 2019. DOI: 10.1200/JCO.19.00022.
15. Михановский А. А. Анализ эффективности комбинированного лечения с неоадъювантной химиотерапией у больных раком яичников / А. А. Михановский, Е. Н. Сухина // Междунар. мед. журн.— 2014.— Т. 20, № 2. — С. 80–87.
16. Карташов С. М. Епідеміологія та діагностика раку яєчників: метод. рек. / С. М. Карташов, О. О. Акуліна, Т. В. Скрицька.— К., 2008. — 25 с.
How to Cite
Kartashov, S. M., BazarіnskaT. V., Tymchenko, M. Y., & Gramatyuk, S. M. (2020). RETROSPECTIVE STUDY AND CURRENT REALITIES AND POSSIBILITIES OF SURGICAL TREATMENT OF OVARIAN CANCER. Kharkiv Surgical School, (2), 201-207.